BACKGROUND: Low bone mineral density (BMD) has been reported among 10%-54% of HIV-infected adolescents in developed countries. We studied the prevalence and predictors of low BMD among HIV-infected Thai adolescents receiving antiretroviral therapy. METHODS: A cross-sectional study of lumbar spine (L2-L4) BMD as measured by dual-energy X-ray absorptiometry in Thai HIV-infected adolescents aged 12-20 years was performed. The BMD Z score was analyzed using age-matched healthy Thai children as a reference. Serum 25-hydroxyvitamin D was performed. Osteopenia was defined as BMD Z score ≤ -2. RESULTS: From October 2010 to February 2011, 101 adolescents, 50% male, with a median age of 14.3 (range: 13.0-15.7) years were enrolled. The median [interquartile range (IQR)] current CD4 T-cell count was 646 (506-796) cells per cubic millimeter and 90% had plasma HIV-1 RNA <50 copies per milliliter. The mean BMD among HIV-infected adolescents and controls were 0.855 and 0.980 g/cm (P < 0.001). The median (IQR) L2-L4 spine BMD Z score was -1.0 (-1.9 to -0.1), of which 24% had BMD Z score ≤ -2.0. The median (IQR) of 25-hydroxyvitamin D level was 24.8 (20.0-31.4) ng/mL, of which 25% had vitamin D level < 20 ng/mL. In multivariate analysis, the height for age Z score < -1.5 (adjusted odds ratio: 6.2; 95% confidence interval: 2.2 to 17.7) and history of World Health Organization clinical stage 4 before antiretroviral therapy (adjusted odds ratio: 3.7; 95% confidence interval: 1.3 to 10.7) were significantly associated with osteopenia. CONCLUSION: One fourth of HIV-infected Thai adolescents have osteopenia. Children with history of advanced-staging or having low height for age are at risk of osteopenia. Preventive measures to prevent osteopenia should be incorporated in routine care for these adolescents.
BACKGROUND: Low bone mineral density (BMD) has been reported among 10%-54% of HIV-infected adolescents in developed countries. We studied the prevalence and predictors of low BMD among HIV-infected Thai adolescents receiving antiretroviral therapy. METHODS: A cross-sectional study of lumbar spine (L2-L4) BMD as measured by dual-energy X-ray absorptiometry in Thai HIV-infected adolescents aged 12-20 years was performed. The BMD Z score was analyzed using age-matched healthy Thai children as a reference. Serum 25-hydroxyvitamin D was performed. Osteopenia was defined as BMD Z score ≤ -2. RESULTS: From October 2010 to February 2011, 101 adolescents, 50% male, with a median age of 14.3 (range: 13.0-15.7) years were enrolled. The median [interquartile range (IQR)] current CD4 T-cell count was 646 (506-796) cells per cubic millimeter and 90% had plasma HIV-1 RNA <50 copies per milliliter. The mean BMD among HIV-infected adolescents and controls were 0.855 and 0.980 g/cm (P < 0.001). The median (IQR) L2-L4 spine BMD Z score was -1.0 (-1.9 to -0.1), of which 24% had BMD Z score ≤ -2.0. The median (IQR) of 25-hydroxyvitamin D level was 24.8 (20.0-31.4) ng/mL, of which 25% had vitamin D level < 20 ng/mL. In multivariate analysis, the height for age Z score < -1.5 (adjusted odds ratio: 6.2; 95% confidence interval: 2.2 to 17.7) and history of World Health Organization clinical stage 4 before antiretroviral therapy (adjusted odds ratio: 3.7; 95% confidence interval: 1.3 to 10.7) were significantly associated with osteopenia. CONCLUSION: One fourth of HIV-infected Thai adolescents have osteopenia. Children with history of advanced-staging or having low height for age are at risk of osteopenia. Preventive measures to prevent osteopenia should be incorporated in routine care for these adolescents.
Authors: Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Pablo Tebas; Laurie Myers; Kathleen Melbourne; Belinda Ha; Paul E Sax Journal: J Infect Dis Date: 2011-06-15 Impact factor: 5.226
Authors: Grace A McComsey; Pablo Tebas; Elizabeth Shane; Michael T Yin; E Turner Overton; Jeannie S Huang; Grace M Aldrovandi; Sandra W Cardoso; Jorge L Santana; Todd T Brown Journal: Clin Infect Dis Date: 2010-10-15 Impact factor: 9.079
Authors: Christine N Dao; Pragna Patel; E Turner Overton; Frank Rhame; Sherri L Pals; Christopher Johnson; Timothy Bush; John T Brooks Journal: Clin Infect Dis Date: 2011-02-01 Impact factor: 9.079
Authors: Hans-Jürgen Stellbrink; Chloe Orkin; Jose Ramon Arribas; Juliet Compston; Jan Gerstoft; Eric Van Wijngaerden; Adriano Lazzarin; Giuliano Rizzardini; Herman G Sprenger; John Lambert; Gunta Sture; David Leather; Sara Hughes; Patrizia Zucchi; Helen Pearce Journal: Clin Infect Dis Date: 2010-10-15 Impact factor: 9.079
Authors: Alexandra Calmy; Christoph A Fux; Richard Norris; Nathalie Vallier; Cécile Delhumeau; Katherine Samaras; Karl Hesse; Bernard Hirschel; David A Cooper; Andrew Carr Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226
Authors: Denise L Jacobson; Jane C Lindsey; Catherine M Gordon; Jack Moye; Dana S Hardin; Kathleen Mulligan; Grace M Aldrovandi Journal: AIDS Date: 2010-03-13 Impact factor: 4.177
Authors: Gayatri Mirani; Paige L Williams; Miriam Chernoff; Mark J Abzug; Myron J Levin; George R Seage; James M Oleske; Murli U Purswani; Rohan Hazra; Shirley Traite; Bonnie Zimmer; Russell B Van Dyke Journal: Clin Infect Dis Date: 2015-08-12 Impact factor: 9.079
Authors: George K Siberry; Denise L Jacobson; Heidi J Kalkwarf; Julia W Wu; Linda A DiMeglio; Ram Yogev; Katherine M Knapp; Justin J Wheeler; Laurie Butler; Rohan Hazra; Tracie L Miller; George R Seage; Russell B Van Dyke; Emily Barr; Mariam Davtyan; Lynne M Mofenson; Kenneth C Rich Journal: Clin Infect Dis Date: 2015-06-09 Impact factor: 9.079
Authors: Aylin B Unsal; Aviva S Mattingly; Sara E Jones; Julia B Purdy; James C Reynolds; Jeffrey B Kopp; Rohan Hazra; Colleen M Hadigan Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Stephen M Arpadi; Stephanie Shiau; Renate Strehlau; Faeezah Patel; Ndileka Mbete; Donald J McMahon; Jonathan J Kaufman; Ashraf Coovadia; Louise Kuhn; Michael T Yin Journal: AIDS Date: 2016-10-23 Impact factor: 4.177